ReviewInternational journal of molecular sciences2020
Emerging Gene-Editing Modalities for Osteoarthritis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Inflammaging and immunosenescence-driven remodeling of the immune microenvironment in osteoarthritis: mechanisms, immune regulation and immune reprogramming.Frontiers in immunology · 2026Review
- Molecular signaling pathways in osteoarthritis and biomaterials for cartilage regeneration: a review.Bioengineered · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Review
- Women's contribution to stem cell research for osteoarthritis: an opinion paper.Frontiers in cell and developmental biology · 2023Review
- Biomaterial-Based Gene Delivery: Advanced Tools for Enhanced Cartilage Regeneration.Drug design, development and therapy · 2023Review
- Role of macrophage polarization in osteoarthritis (Review).Experimental and therapeutic medicine · 2022Review
- Engineering Closed-Loop, Autoregulatory Gene Circuits for Osteoarthritis Cell-Based Therapies.Current rheumatology reports · 2022Review
- Two-Dimensional and Three-Dimensional Cartilage Model Platforms for Drug Evaluation and High-Throughput Screening Assays.Tissue engineering. Part B, Reviews · 2022Review
- Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics.Theranostics · 2022Review
- Methods of Modification of Mesenchymal Stem Cells and Conditions of Their Culturing for Hyaline Cartilage Tissue Engineering.Biomedicines · 2021Review
- Control of the Autophagy Pathway in Osteoarthritis: Key Regulators, Therapeutic Targets and Therapeutic Strategies.International journal of molecular sciences · 2021Review
- Update on Novel Non-Operative Treatment for Osteoarthritis: Current Status and Future Trends.Frontiers in pharmacology · 2021Review
- Research of Pathogenesis and Novel Therapeutics in Arthritis 2.0.International journal of molecular sciences · 2020Article
- Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- Pain sensitivity genes as therapeutic targets in knee osteoarthritis: A comprehensive analysis.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Osteoarthritis (OA) is a pathological degenerative condition of the joints that is widely prevalent worldwide, resulting in significant pain, disability, and impaired quality of life. The diverse etiology and pathogenesis of OA can explain the paucity of viable preventive and disease-modifying strategies to counter it. Advances in genome-editing techniques may improve disease-modifying solutions by addressing inherited predisposing risk factors and the activity of inflammatory modulators. Recent progress on technologies such as CRISPR/Cas9 and cell-based genome-editing therapies targeting the genetic and epigenetic alternations in OA offer promising avenues for early diagnosis and the development of personalized therapies. The purpose of this literature review was to concisely summarize the genome-editing options against chronic degenerative joint conditions such as OA with a focus on the more recently emerging modalities, especially CRISPR/Cas9. Future advancements in novel genome-editing therapies may improve the efficacy of such targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.